Literature DB >> 11607801

Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men.

A Mahmud1, M Hennessy, J Feely.   

Abstract

As the effects of sildenafil are in part mediated by enhancing the action of nitric oxide and nitrates given acutely markedly reduce early wave reflection, we explored the effects of a single oral dose of sildenafil citrate (50 mg) on blood pressure and arterial wave reflection in treated hypertensive men in a single-blind randomised placebo controlled crossover study. Eight men (aged 57-76 years) with well controlled hypertension and erectile dysfunction and no contraindications to the use of sildenafil, were given either sildenafil 50 mg or placebo orally, with the second drug being given 2 weeks later. Blood pressure and heart rate with an automated digital oscillometric device (Omron) HEM-705 CP) and the augmentation index, a measure of arterial wave reflection in the aorta derived using radial applanation tonometry, were measured before and at 15-min intervals for 2 h thereafter. The extent of individual maximum reductions (mm Hg) from baseline in systolic (24 +/- 10 vs. 6 +/- 8, P < 0.05) and diastolic blood pressure (8 +/- 5 vs. 3 +/- 2, P < 0.05) occurred on the sildenafil study day. On average the brachial blood pressure at 75 min following sildenafil was 17/11 mm less than on the placebo day (P < 0.01). Augmentation index was also reduced significantly at 90 min (P < 0.05) suggesting reduced vascular tone in the arteries. The area under the brachial and aortic blood pressure and augmentation index time curve (by the trapezoidal rule corrected for baseline reading) was significantly lower (P < 0.05) on the sildenafil study day. The study shows that the peripheral vasodilatory effects of sildenafil, possibly related to nitric oxide, are accompanied by a fall in systemic blood pressure and reduced arterial wave reflection.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11607801     DOI: 10.1038/sj.jhh.1001244

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  15 in total

1.  Hemodynamic effects of sildenafil citrate (Viagra) on segmental branches of bilateral renal arteries.

Authors:  Arslan Ardicoglu; Ercan Kocakoc; Veysel Yuzgec; Zulkif Bozgeyik; Halit Canatan; Adem Kiris
Journal:  Int Urol Nephrol       Date:  2005       Impact factor: 2.370

Review 2.  Phosphodiesterase-5 inhibitors and their hemodynamic effects.

Authors:  L Michael Prisant
Journal:  Curr Hypertens Rep       Date:  2006-08       Impact factor: 5.369

3.  Sildenafil enhances central hemodynamic responses to exercise, but not V̇o2peak, in people with diabetes mellitus.

Authors:  Timothy J Roberts; Andrew T Burns; Richard J MacIsaac; Andrew I MacIsaac; David L Prior; André La Gerche
Journal:  J Appl Physiol (1985)       Date:  2019-05-02

4.  PhosphdiesteRasE-5 Inhibition to Improve CLinical Status and EXercise Capacity in Diastolic Heart Failure (RELAX) trial: rationale and design.

Authors:  Margaret M Redfield; Barry A Borlaug; Greg D Lewis; Selma F Mohammed; Marc J Semigran; Martin M Lewinter; Anita Deswal; Adrian F Hernandez; Kerry L Lee; Eugene Braunwald
Journal:  Circ Heart Fail       Date:  2012-09-01       Impact factor: 8.790

5.  Haemodynamic effects of the selective phosphodiesterase 5 inhibitor, UK-357,903, in conscious SHR.

Authors:  Sheila M Gardiner; Julie E March; Philip A Kemp; Stephen A Ballard; Ed Hawkeswood; Bernadette Hughes; Terence Bennett
Journal:  Br J Pharmacol       Date:  2003-12-08       Impact factor: 8.739

Review 6.  Sildenafil and phosphodiesterase-5 inhibitors for heart failure.

Authors:  Marco Guazzi
Journal:  Curr Heart Fail Rep       Date:  2008-06

Review 7.  Phosphodiesterase inhibition in heart failure.

Authors:  Matthew Movsesian; Josef Stehlik; Fabrice Vandeput; Michael R Bristow
Journal:  Heart Fail Rev       Date:  2008-12-19       Impact factor: 4.214

Review 8.  Phosphodiesterase 5 inhibition in essential hypertension.

Authors:  Lorenzo Ghiadoni; Daniele Versari; Stefano Taddei
Journal:  Curr Hypertens Rep       Date:  2008-02       Impact factor: 5.369

Review 9.  Phosphodiesterase type 5 inhibitors and kidney disease.

Authors:  Baris Afsar; Alberto Ortiz; Adrian Covic; Abduzhappar Gaipov; Tarik Esen; David Goldsmith; Mehmet Kanbay
Journal:  Int Urol Nephrol       Date:  2015-08-05       Impact factor: 2.370

10.  Muscle-Powered Counterpulsation for Untethered, Non-Blood-Contacting Cardiac Support: A Path to Destination Therapy.

Authors:  Jooli Han; Edgar Aranda-Michel; Dennis R Trumble
Journal:  IEEE Trans Biomed Eng       Date:  2020-02-18       Impact factor: 4.538

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.